NRX Pharmaceuticals Inc. (NASDAQ: NRXP)
$2.54
+0.1500 ( +6.28% ) 95.8K
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Market Data
Open
$2.54
Previous close
$2.39
Volume
95.8K
Market cap
$26.75M
Day range
$2.37 - $2.54
52 week range
$1.90 - $7.33
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jan 23, 2024 |
3 | Insider transactions | 1 | Jan 16, 2024 |
8-k | 8K-related | 14 | Dec 29, 2023 |
pre | Proxies and info statements | 4 | Dec 29, 2023 |
8-k | 8K-related | 13 | Dec 21, 2023 |
ars | Annual reports | 1 | Nov 22, 2023 |
def | Proxies and info statements | 6 | Nov 22, 2023 |
8-k/a | 8K-related | 16 | Nov 22, 2023 |
8-k | 8K-related | 13 | Nov 21, 2023 |
8-k | 8K-related | 15 | Nov 14, 2023 |